Velagliflozin proline is an oral sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations. In Vivo Velagliflozin (1 mg/kg; p.o.; single dose) proline increases cholesterol, albumin, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), and urinary glucose excretion, and decreases respiratory exchange ratio in cats . Velagliflozin (0.3 mg/kg; p.o.; once daily for 18 d) proline is well tolerated and can improve insulin disorders and prevent laminitis in ponies by reducing the high insulin response of dietary non-structural carbohydrates (NSC). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid-liquid mixture